These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16157895)

  • 1. LRRK2: both a cause and a risk factor for Parkinson disease?
    Foroud T
    Neurology; 2005 Sep; 65(5):664-5. PubMed ID: 16157895
    [No Abstract]   [Full Text] [Related]  

  • 2. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations.
    Zabetian CP; Samii A; Mosley AD; Roberts JW; Leis BC; Yearout D; Raskind WH; Griffith A
    Neurology; 2005 Sep; 65(5):741-4. PubMed ID: 16157909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 gene in Parkinson disease: mutation analysis and case control association study.
    Paisán-Ruíz C; Lang AE; Kawarai T; Sato C; Salehi-Rad S; Fisman GK; Al-Khairallah T; St George-Hyslop P; Singleton A; Rogaeva E
    Neurology; 2005 Sep; 65(5):696-700. PubMed ID: 16157901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 mutations in Parkinson disease.
    Farrer M; Stone J; Mata IF; Lincoln S; Kachergus J; Hulihan M; Strain KJ; Maraganore DM
    Neurology; 2005 Sep; 65(5):738-40. PubMed ID: 16157908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticobasal syndrome and primary progressive aphasia as manifestations of lrrk2 gene mutations.
    Ross OA; Toft M; Haugarvoll K
    Neurology; 2008 Jul; 71(4):303; author reply 303-4. PubMed ID: 18645174
    [No Abstract]   [Full Text] [Related]  

  • 6. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
    Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
    Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of LRRK2 functional domains in nondominant Parkinson disease.
    Skipper L; Shen H; Chua E; Bonnard C; Kolatkar P; Tan LC; Jamora RD; Puvan K; Puong KY; Zhao Y; Pavanni R; Wong MC; Yuen Y; Farrer M; Liu JJ; Tan EK
    Neurology; 2005 Oct; 65(8):1319-21. PubMed ID: 16247070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
    Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
    Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 screening in a Canadian Parkinson's disease cohort.
    Grimes DA; Racacho L; Han F; Panisset M; Bulman DE
    Can J Neurol Sci; 2007 Aug; 34(3):336-8. PubMed ID: 17803033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ancestry of LRRK2 Gly2019Ser parkinsonism.
    Benamer HT
    Lancet Neurol; 2008 Sep; 7(9):769-70; author reply 770-1. PubMed ID: 18702998
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.
    Ishihara L; Warren L; Gibson R; Amouri R; Lesage S; Dürr A; Tazir M; Wszolek ZK; Uitti RJ; Nichols WC; Griffith A; Hattori N; Leppert D; Watts R; Zabetian CP; Foroud TM; Farrer MJ; Brice A; Middleton L; Hentati F
    Arch Neurol; 2006 Sep; 63(9):1250-4. PubMed ID: 16966502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of LRRK2 mutations and Parkinson's disease in Brazil.
    Pimentel MM; Moura KC; Abdalla CB; Pereira JS; de Rosso AL; Nicaretta DH; Campos M; de Almeida RM; dos Santos JM; Bastos IC; Mendes MF; Maultasch H; Costa FH; Werneck AL; Santos-Rebouças CB
    Neurosci Lett; 2008 Mar; 433(1):17-21. PubMed ID: 18201824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation.
    Johnson J; Paisán-Ruíz C; Lopez G; Crews C; Britton A; Malkani R; Evans EW; McInerney-Leo A; Jain S; Nussbaum RL; Foote KD; Mandel RJ; Crawley A; Reimsnider S; Fernandez HH; Okun MS; Gwinn-Hardy K; Singleton AB
    Neurodegener Dis; 2007; 4(5):386-91. PubMed ID: 17622782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease.
    Haubenberger D; Bonelli S; Hotzy C; Leitner P; Lichtner P; Samal D; Katzenschlager R; Djamshidian A; Brücke T; Steffelbauer M; Bancher C; Grossmann J; Ransmayr G; Strom TM; Meitinger T; Gasser T; Auff E; Zimprich A
    Mov Disord; 2007 Aug; 22(11):1640-3. PubMed ID: 17523199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8.
    Nichols WC; Elsaesser VE; Pankratz N; Pauciulo MW; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T;
    Neurology; 2007 Oct; 69(18):1737-44. PubMed ID: 17804834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population.
    Funayama M; Li Y; Tomiyama H; Yoshino H; Imamichi Y; Yamamoto M; Murata M; Toda T; Mizuno Y; Hattori N
    Neuroreport; 2007 Feb; 18(3):273-5. PubMed ID: 17314670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mutation in LRRK2 is associated with familial presentation of Parkinson's disease in a Chilean kindred].
    Miranda M
    Rev Med Chil; 2007 Mar; 135(3):406-7. PubMed ID: 17505590
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8.
    Bonifati V; Wu-Chou YH; Schweiger D; Fonzo AD; Lu CS; Oostra B
    Neurology; 2008 Jun; 70(24):2348; author reply 2348-9. PubMed ID: 18541891
    [No Abstract]   [Full Text] [Related]  

  • 19. A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations.
    Lohmann E; Leclere L; De Anna F; Lesage S; Dubois B; Agid Y; Dürr A; Brice A;
    Parkinsonism Relat Disord; 2009 May; 15(4):273-6. PubMed ID: 18718805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low disease risk in relatives of north african lrrk2 Parkinson disease patients.
    Troiano AR; Elbaz A; Lohmann E; Belarbi S; Vidailhet M; Bonnet AM; Lesage S; Pollak P; Cazeneuve C; Borg M; Feingold J; Dürr A; Tazir M; Brice A;
    Neurology; 2010 Sep; 75(12):1118-9. PubMed ID: 20855856
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.